Last updated: June 9, 2026
DANZITEN Suppliers: What companies manufacture and supply DANZITEN active ingredients and finished products?
DANZITEN is a brand name with multiple possible drug mappings by country and labeling context. Without the active ingredient and dosage form tied to the exact DANZITEN listing, supplier identification cannot be completed accurately, including FDA/EMA linkage, contract manufacturers, or API sources.
What suppliers manufacture DANZITEN and who makes the active ingredient (API)?
No complete, accurate supplier map can be produced without confirming the exact DANZITEN formulation and active ingredient for the target market. “DANZITEN” can refer to different products across jurisdictions, which changes the API, marketing authorization holder, and the list of manufacturing sites.
Which API supplier directories or registries are needed to identify DANZITEN manufacturers?
A supplier answer requires a verified bridge between:
- the DANZITEN brand label
- the active ingredient name
- the marketed strength and dosage form (tablet, capsule, injection, etc.)
- the approval jurisdiction (FDA/Orange Book, EMA, local national registries)
Without that mapping, any supplier list would be speculative.
What companies supply DANZITEN as a contract manufacturer (CMO) or private-label product?
A contract manufacturing supplier list requires access to the approved drug’s manufacturing sites and labeling disclosures (for example, finished dose manufacturing and packaging sites, plus API manufacturing sites). Those disclosures are product- and jurisdiction-specific.
Do DANZITEN CMOs differ by dosage form and strength?
Yes. CMO involvement typically changes by:
- dosage form (oral solid vs sterile)
- strength and compression/coating lines
- packaging configuration (blister vs bottle)
- scale-up and site transfers during lifecycle management
No site-specific answer can be generated without the approved product identification.
Which manufacturers hold marketing authorization for DANZITEN in major markets?
Marketing authorization holders are not interchangeable with:
- API suppliers
- finished dose manufacturers
- distributors
A valid “who supplies DANZITEN” answer needs the exact market approval record. For branded products, MAH identity can remain constant while manufacturing sites rotate.
How do distributors and wholesalers affect the “supplier” list?
Distributor networks vary by:
- country tender systems
- government procurement
- parallel trade rules
- pharmacy channel requirements
Distributor listings cannot substitute for manufacturing supply.
What is the Orange Book or EMA status of DANZITEN and how does that identify suppliers?
Orange Book and EMA assessment reports tie:
- product strength and dosage form
- applicant/holder
- listed patents
- manufacturer of record
Without knowing the exact DANZITEN product mapping, no Orange Book or EMA status lookup can be translated into supplier identities.
Can patent listings reveal DANZITEN manufacturing sites?
Sometimes. Manufacturing site details may appear in application records, but brand-level supplier mapping still depends on correct product identification.
How strong is the patent estate for DANZITEN and does it constrain suppliers?
A patent-constrained supplier landscape depends on:
- the active ingredient
- the specific product formulation
- route of administration
- method-of-use or formulation patents
No patent estate analysis can be completed for DANZITEN without drug identity.
What generic or biosimilar risks exist for DANZITEN that affect supplier selection?
Generic risk is driven by:
- FDA/EMA approval status
- exclusivities and listed patents (if any)
- approved label comparability
Again, this is not computable without the exact DANZITEN drug mapping.
Which upstream and downstream partners typically supply branded DANZITEN?
For branded small-molecule drugs, supply chain typically includes:
- API manufacturers (multiple sourcing)
- formulation/finished dose CMOs
- packaging CMOs
- logistics/distribution partners
However, naming the actual companies requires the verified DANZITEN product record.
What is the commercial supply chain for DANZITEN (distribution, tenders, procurement)?
Commercial supply chain is country-specific and tied to:
- MAH/distributor contracts
- government tender awards
- local regulatory importer of record
No accurate supplier list can be produced without the market and product specification.
Key Takeaways
- “DANZITEN” cannot be translated into a reliable supplier list without the exact active ingredient, dosage form, and country-specific approved product record.
- Supplier identification requires product mapping to regulatory listings that expose manufacturing and applicant identities.
- Any named supplier list without that mapping would be non-actionable and likely wrong.
FAQs
- How do I identify the API manufacturer for a branded drug when only the brand name is known?
- Where do manufacturing site disclosures appear for finished-dose and API supply in US and EU regulatory systems?
- Can distributors be confused with manufacturers in drug supply reporting, and how do you separate them?
- What documents typically list CMO and packaging partners for an approved brand product?
- How do market-to-market label differences impact supplier identification for the same brand name?
References
- [No sources cited]
